6 results on '"Abe, S"'
Search Results
2. Evaluation of Spatial Resolution for Heavy Ion CT System Based on the Measurement of Residual Range Distribution With HIMAC.
- Author
-
Muraishi, H., Nishimura, K., Abe, S., Satoh, H., Hara, S., Hara, H., Takahashi, Y., Mogaki, T., Kawai, R., Yokoyama, K., Yasuda, N., Tomida, T., Ohno, Y., and Kanai, T.
- Subjects
- *
CHARGE coupled devices , *TOMOGRAPHY , *HEAVY ions , *PROTON therapy , *CCD cameras , *X-rays , *NUCLEAR science , *THERAPEUTICS - Abstract
We report experimental results from a heavy ion CT system based on the measurement of residual range distribution using an X-ray intensifying screen and a charged coupled device (CCD) camera system. This technique was first investigated by Zygmanski et al. (2000) for proton beams, and they reported that the spatial resolution was significantly degraded by multiple Coulomb scattering (MCS) effects in the irradiated medium. Experiments were done on the spatial resolution phantom by using helium and carbon beams accelerated up to 120 MeV/u and 230 MeV/u by the Heavy Ion Medical Accelerator in Chiba (HIMAC), installed in the National Institute of Radiological Sciences (NIRS) in Japan, using a high performance intensified CCD (ICCD) camera. We show that the MCS blurring effect can be significantly reduced in the reconstructed image by using a carbon beam with this technique. Our results suggest that heavier particles such as carbon would be more useful if this technique is envisioned as a clinical tool to obtain data that would aid proton and/or heavy ion treatment planning. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
3. Magnetic resonance imaging can reveal fascial vasculitis in a patient with microscopic polyangiitis.
- Author
-
Takahashi, H, Tsuboi, H, Abe, S, Yokosawa, M, Hagiwara, S, Asashima, H, Hirota, T, Umeda, N, Kondo, Y, Matsumoto, I, and Sumida, T
- Subjects
- *
VASCULITIS , *MAGNETIC resonance imaging , *PATIENTS , *PREDNISOLONE , *FASCIAE (Anatomy) , *TREATMENT effectiveness , *SKELETAL muscle , *DISEASE complications , *DIAGNOSIS , *THERAPEUTICS - Abstract
A letter to the editor is presented regarding the article on the use of magnetic resonance imaging to determine the fascial vasculitis in a patient with microscopic polyangiitis.
- Published
- 2015
- Full Text
- View/download PDF
4. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.
- Author
-
Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S, Otsuka, M, Takahashi, H, Shiratori, M, Chiba, H, and Abe, S
- Subjects
- *
BLEOMYCIN , *PULMONARY fibrosis , *ANGIOTENSIN I , *HEART fibrosis , *PROTEIN analysis , *BIPHENYL compounds , *ANIMALS , *ANTINEOPLASTIC antibiotics , *BODY fluids , *CELL receptors , *GROWTH factors , *HETEROCYCLIC compounds , *IMMUNOHISTOCHEMISTRY , *PROLINE , *RATS , *WESTERN immunoblotting , *ALBUMINS , *ANGIOTENSIN receptors , *THERAPEUTICS - Abstract
Background: Signalling of angiotensin II via angiotensin II type 1 receptor (AT1) promotes cardiac and renal fibrosis, but its role in lung fibrosis is little understood. Using a rat bleomycin (BLM) induced model of pulmonary fibrosis, we examined the expression of AT1 in the lung and the effect of an AT1 antagonist on pulmonary fibrosis.Methods: Adult male Sprague-Dawley rats were given 0.3 mg/kg BLM intratracheally. Two days earlier they had received 10 mg/kg/day of the AT1 antagonist candesartan cilexetil mixed in the drinking water. AT1 expression in the lungs was examined by immunohistochemistry and immunoblot methods. The effect of the AT1 antagonist on pulmonary fibrosis was studied by analysis of bronchoalveolar lavage (BAL) fluid, histopathology, and hydroxyproline assay.Results: Immunohistochemical studies showed overexpression of AT1 in inflammatory immune cells, alveolar type II cells, and fibroblasts. A quantitative assay for AT1 showed that AT1 expression was significantly upregulated in cells from BAL fluid after day 3 and in the lung homogenates after day 21. Candesartan cilexetil significantly inhibited the increase in total protein and albumin, as well as the increase in total cells and neutrophils in BAL fluid. On day 21 candesartan cilexetil also ameliorated morphological changes and an increased amount of hydroxyproline in lung homogenates. In addition, BLM increased the expression of transforming growth factor (TGF)-beta1 in BAL fluid on day 7; this increase was significantly reduced by candesartan cilexetil.Conclusion: AT1 expression is upregulated in fibrotic lungs. Angiotensin II promotes lung fibrosis via AT1 and, presumably, in part via TGF-beta1. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
5. Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
- Author
-
Fujita, A., Ohkubo, T., Hoshino, H., Takabatake, H., Tagaki, S., Sekine, K., and Abe, S.
- Subjects
- *
GRANULOCYTES , *LUNG cancer treatment , *CISPLATIN , *TOXICITY testing , *CANCER chemotherapy , *GRANULOCYTE-colony stimulating factor , *ADENOCARCINOMA , *ANTINEOPLASTIC agents , *CAMPTOTHECIN , *CANCER , *CLINICAL trials , *COMPARATIVE studies , *DOSE-effect relationship in pharmacology , *LUNG cancer , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *RECOMBINANT proteins , *RESEARCH , *SQUAMOUS cell carcinoma , *SURVIVAL , *TUMOR classification , *EVALUATION research , *IFOSFAMIDE , *THERAPEUTICS - Abstract
A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998 and August 2001, 50 patients were registered in this phase II study. Cisplatin (20 mg m(-2)) and ifosfamide (1.5 g m(-2)) were administered on days 1-4 and irinotecan (60 mg m(-2)) was given on days 1, 8, and 15, respectively. This regimen was repeated every 4 weeks. rhG-CSF was administered subcutaneously at a dose of 50 microg m(-2) on days 5-18 except on the days of irinotecan treatment. In total, 49 patients were assessable for toxicity and response and 50 for survival. In all, 33, patients (67.3%; 95% confidence interval 57.4-77.2%) achieved an objective response. The median response duration was 192 days and the median time to progression for 49 patients was 170 days. The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively. Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively. In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
6. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy.
- Author
-
Yamada, Gen, Igarashi, Tomofumi, Itoh, Eiji, Tanaka, Hiroshi, Sekine, Kyuichiro, Abe, Shosaku, Yamada, G, Igarashi, T, Itoh, E, Tanaka, H, Sekine, K, and Abe, S
- Subjects
- *
ERYTHROMYCIN , *BRONCHITIS , *AIRWAY (Anatomy) , *THERAPEUTICS - Abstract
Background: Low-dose erythromycin therapy improves airflow limitation and airway inflammation in patients with diffuse panbronchiolitis (DPB). However, to our knowledge there has been no study to determine whether physiologic improvement during erythromycin therapy correlates with radiologic findings.Study Objective: To clarify whether improvement in pulmonary function correlates with specific changes on chest CT.Design: The relationship between five CT findings and five pulmonary function parameters was evaluated before and 3 months after low-dose erythromycin therapy in 24 patients with DPB retrospectively.Results: After erythromycin therapy, the predicted percentage of vital capacity (%VC; 87.0 +/- 3.07% vs 98.9 +/- 3.39%; p = 0.00006) and 50% of the maximum midexpiratory flow rate of FVC (1.41 +/- 0.26 L/s vs 1.61 +/- 0.27 L/s; p = 0.03) significantly increased, and the residual volume/total lung capacity ratio (RV/TLC%; 44.5 +/- 1.93% vs 40.7 +/- 1.83%; p = 0.0019) significantly decreased, but the FEV(1) to FVC ratio and 25% of the maximum expiratory flow rate of FVC did not. In five CT findings, centrilobular nodules (3.7 +/- 0.4 vs 1.5 +/- 0.3; p = 0.0001), peripheral bronchiolar wall thickness (3.8 +/- 0.3 vs 2.6 +/- 0.4; p = 0.0007), and peripheral bronchiolectasis (2.8 +/- 0.3 vs 2.2 +/- 0.4; p = 0.0058) had significantly improved, whereas low attenuation area and central bronchiectasis had not. There were positive correlations of improved scores of centrilobular nodules with improved %VC (r = 0.58, p = 0.0062) and RV/TLC% (r = 0.64, p = 0.0022).Conclusions: Decreased air trapping in DPB correlates with an improvement of centrilobular nodules, which reflects the obstructive lesions of bronchioles during the erythromycin therapy. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.